The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a broader re-evaluation of consumer staple portfolios, Everstar Asset Management LLC reduced its stake in The Clorox Company by 62.5% in the first quarter of 2026. Conversely, Director Pierre R. Breber increased his ownership in Clorox by 38.46% through an insider purchase. Despite this internal vote of confidence, analysts maintain a 'Reduce' rating on the stock with an average price target of $103.40.
Sign in to access this content
Sign InThis institutional sell-off occurs as the household products sector navigates mixed demand signals; for context, peer company Procter & Gamble (PG) recently reported a 3% organic sales growth in its latest quarterly filing. The cautious stance on CLX reflects broader industry concerns, as the stock's current valuation remains sensitive to margin pressures compared to its larger-cap competitors per market data.
CLX shares stood at $95.80 at the close of June 18, 2026, after hitting a session high of $97.81. Investors are now looking toward upcoming U.S. economic catalysts, including Retail Sales data scheduled for June 16, 2026, which will provide critical insight into consumer spending resilience and its impact on the staples sector.